The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor - PubMed (original) (raw)
The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor
J Davies et al. J Cell Biol. 1989 Oct.
Abstract
We have defined the structure of the Osteoclast Functional Antigen (OFA) by immunological and biochemical means. OFA is an abundant surface antigen in human and animal osteoclasts and has been characterized previously by monoclonal antibodies 13C2 and 23C6, one of which mimicks the inhibitory activity of calcitonin on osteoclastic bone resorption. By the following criteria we show that OFA is a member of the integrin family of extracellular matrix receptors and is identical, or at least highly related, to the vitronectin receptor (VNR) previously isolated from placenta and melanoma cells. Immunoprecipitation analysis demonstrates that OFA from osteoclasts and a monkey kidney cell line Vero is a heterodimeric molecule of 140 kD (alpha chain) and 85 kD (beta chain) under nonreducing conditions; on reduction at least one low molecular mass (alpha') species (of approximately 30-kD size) is released, resulting in a 120/100-kD dimer. Immunoblots of OFA isolated from osteoclasts and Vero cells and VNR purified from placenta and probed with heterosera to OFA and monoclonal antibodies to platelet gp111a (VNR beta chain) show immunological cross-reactivity between the alpha chains of OFA and VNR and the use of gp111a as a beta chain by both. OFA from Vero cells binds to an Arg-Gly-Asp containing peptide (GRGDSPPK) isolating a heterodimer recognized by anti-OFA monoclonal antibodies, 13C2 and 23C6. Immunohistochemical analysis showed a similar tissue distribution in humans for the antigen recognized by anti-OFA antibodies, a monoclonal antibody, LM142, raised to melanoma VNR, polyclonal antibodies to the placental VNR and a monoclonal antibody to the presumptive VNR beta chain, platelet glycoprotein 111a. Finally, NH2 terminal amino acid sequencing showed that the amino-terminus of the monkey alpha chain was identical in the 12 assigned residues to that of human VNR alpha chain. The beta chain sequence of OFA differed at least 1 (and up to 4) positions from platelet gp111a (VNR beta) in the first 18 amino acids sequenced. These, and other, data provide the first indication of a function for the VNR and suggest that cell-cell and cell-extracellular matrix interactions involving integrins may play an important role in bone physiology.
Similar articles
- Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.
Horton MA, Taylor ML, Arnett TR, Helfrich MH. Horton MA, et al. Exp Cell Res. 1991 Aug;195(2):368-75. doi: 10.1016/0014-4827(91)90386-9. Exp Cell Res. 1991. PMID: 1712731 - Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation.
Rabinowich H, Lin WC, Amoscato A, Herberman RB, Whiteside TL. Rabinowich H, et al. J Immunol. 1995 Feb 1;154(3):1124-35. J Immunol. 1995. PMID: 7529790 - Blood leukocytes bind platelet glycoprotein (IIb-IIIa)' but do not express the vitronectin receptor.
Krissansen GW, Lucas CM, Stomski FC, Elliott MJ, Berndt MC, Boyd AW, Horton MA, Cheresh DA, Vadas MA, Burns GF. Krissansen GW, et al. Int Immunol. 1990;2(3):267-77. doi: 10.1093/intimm/2.3.267. Int Immunol. 1990. PMID: 1708278 - Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
Dresner-Pollak R, Rosenblatt M. Dresner-Pollak R, et al. J Cell Biochem. 1994 Nov;56(3):323-30. doi: 10.1002/jcb.240560308. J Cell Biochem. 1994. PMID: 7876325 Review. - Integrin function in osteoclasts.
Rodan SB, Rodan GA. Rodan SB, et al. J Endocrinol. 1997 Sep;154 Suppl:S47-56. J Endocrinol. 1997. PMID: 9379137 Review.
Cited by
- Toward a Mathematical Modeling of Diseases' Impact on Bone Remodeling: Technical Review.
Ait Oumghar I, Barkaoui A, Chabrand P. Ait Oumghar I, et al. Front Bioeng Biotechnol. 2020 Nov 2;8:584198. doi: 10.3389/fbioe.2020.584198. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33224935 Free PMC article. Review. - A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy.
Zur Y, Rosenfeld L, Keshelman CA, Dalal N, Guterman-Ram G, Orenbuch A, Einav Y, Levaot N, Papo N. Zur Y, et al. PLoS Biol. 2018 Aug 24;16(8):e2002979. doi: 10.1371/journal.pbio.2002979. eCollection 2018 Aug. PLoS Biol. 2018. PMID: 30142160 Free PMC article. - 64Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases.
Ocak M, Beaino W, White A, Zeng D, Cai Z, Anderson CJ. Ocak M, et al. Cancer Biother Radiopharm. 2018 Mar;33(2):74-83. doi: 10.1089/cbr.2017.2419. Cancer Biother Radiopharm. 2018. PMID: 29634417 Free PMC article. - A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.
Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, Schellens JH, Lolkema MP. Cirkel GA, et al. Invest New Drugs. 2016 Apr;34(2):184-92. doi: 10.1007/s10637-015-0320-9. Epub 2016 Jan 20. Invest New Drugs. 2016. PMID: 26792581 Free PMC article. Clinical Trial. - The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction.
Adamopoulos IE, Pflanz S. Adamopoulos IE, et al. Cytokine Growth Factor Rev. 2013 Apr;24(2):115-21. doi: 10.1016/j.cytogfr.2012.10.001. Epub 2012 Nov 16. Cytokine Growth Factor Rev. 2013. PMID: 23165310 Free PMC article. Review.
References
- J Histochem Cytochem. 1987 Jul;35(7):707-15 - PubMed
- Br J Exp Pathol. 1989 Jun;70(3):257-65 - PubMed
- Cell. 1987 Feb 27;48(4):549-54 - PubMed
- Nature. 1970 Aug 15;227(5259):680-5 - PubMed
- Eur J Biochem. 1974 Jul 1;46(1):83-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources